Free Trial
→ Iran's New Leader Just Said Something That Should Terrify Every American (From American Alternative) (Ad)tc pixel Free OASM Stock Alerts

This company has been marked as potentially delisted and may not be actively trading.

Oasmia Pharmaceutical AB (publ) (OASM) Competitors

Compare

OASM vs. VAXX, ASLN, EVFM, GRAY, and ATHX

Should you be buying Oasmia Pharmaceutical AB (publ) stock or one of its competitors? The main competitors of Oasmia Pharmaceutical AB (publ) include Vaxxinity (VAXX), ASLAN Pharmaceuticals (ASLN), Evofem Biosciences (EVFM), Graybug Vision (GRAY), and Athersys (ATHX). These companies are all part of the "medical" sector.

How does Oasmia Pharmaceutical AB (publ) compare to Vaxxinity?

Oasmia Pharmaceutical AB (publ) (NASDAQ:OASM) and Vaxxinity (NASDAQ:VAXX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation, institutional ownership and media sentiment.

In the previous week, Oasmia Pharmaceutical AB (publ)'s average media sentiment score of 0.00 equaled Vaxxinity'saverage media sentiment score.

Company Overall Sentiment
Oasmia Pharmaceutical AB (publ) Neutral
Vaxxinity Neutral

Oasmia Pharmaceutical AB (publ) has higher revenue and earnings than Vaxxinity.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oasmia Pharmaceutical AB (publ)$220K0.00-$18.95MN/AN/A
VaxxinityN/AN/A-$56.93M-$0.45N/A

Oasmia Pharmaceutical AB (publ) has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500. Comparatively, Vaxxinity has a beta of -74.37, meaning that its share price is 7,537% less volatile than the S&P 500.

Vaxxinity has a net margin of 0.00% compared to Oasmia Pharmaceutical AB (publ)'s net margin of -8,633.64%. Vaxxinity's return on equity of 0.00% beat Oasmia Pharmaceutical AB (publ)'s return on equity.

Company Net Margins Return on Equity Return on Assets
Oasmia Pharmaceutical AB (publ)-8,633.64% -43.94% -28.92%
Vaxxinity N/A N/A N/A

0.1% of Oasmia Pharmaceutical AB (publ) shares are held by institutional investors. Comparatively, 82.9% of Vaxxinity shares are held by institutional investors. 64.1% of Vaxxinity shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Vaxxinity beats Oasmia Pharmaceutical AB (publ) on 5 of the 8 factors compared between the two stocks.

How does Oasmia Pharmaceutical AB (publ) compare to ASLAN Pharmaceuticals?

Oasmia Pharmaceutical AB (publ) (NASDAQ:OASM) and ASLAN Pharmaceuticals (NASDAQ:ASLN) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, media sentiment, valuation, dividends, profitability, analyst recommendations and institutional ownership.

0.1% of Oasmia Pharmaceutical AB (publ) shares are held by institutional investors. Comparatively, 58.8% of ASLAN Pharmaceuticals shares are held by institutional investors. 4.7% of ASLAN Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Oasmia Pharmaceutical AB (publ)'s average media sentiment score of 0.00 equaled ASLAN Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Oasmia Pharmaceutical AB (publ) Neutral
ASLAN Pharmaceuticals Neutral

Oasmia Pharmaceutical AB (publ) has a beta of 0.96, indicating that its share price is 4% less volatile than the S&P 500. Comparatively, ASLAN Pharmaceuticals has a beta of 1.4, indicating that its share price is 40% more volatile than the S&P 500.

Oasmia Pharmaceutical AB (publ) has higher earnings, but lower revenue than ASLAN Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oasmia Pharmaceutical AB (publ)$220K0.00-$18.95MN/AN/A
ASLAN Pharmaceuticals$12M0.10-$44.22M-$21.92N/A

ASLAN Pharmaceuticals has a net margin of 0.00% compared to Oasmia Pharmaceutical AB (publ)'s net margin of -8,633.64%. Oasmia Pharmaceutical AB (publ)'s return on equity of -43.94% beat ASLAN Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Oasmia Pharmaceutical AB (publ)-8,633.64% -43.94% -28.92%
ASLAN Pharmaceuticals N/A -8,454.87%-121.60%

Summary

ASLAN Pharmaceuticals beats Oasmia Pharmaceutical AB (publ) on 5 of the 8 factors compared between the two stocks.

How does Oasmia Pharmaceutical AB (publ) compare to Evofem Biosciences?

Evofem Biosciences (NASDAQ:EVFM) and Oasmia Pharmaceutical AB (publ) (NASDAQ:OASM) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, media sentiment, earnings, analyst recommendations, valuation and profitability.

Evofem Biosciences has higher revenue and earnings than Oasmia Pharmaceutical AB (publ).

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evofem Biosciences$11.39M0.07$52.98M-$0.03N/A
Oasmia Pharmaceutical AB (publ)$220K0.00-$18.95MN/AN/A

In the previous week, Evofem Biosciences had 1 more articles in the media than Oasmia Pharmaceutical AB (publ). MarketBeat recorded 1 mentions for Evofem Biosciences and 0 mentions for Oasmia Pharmaceutical AB (publ). Evofem Biosciences' average media sentiment score of 1.34 beat Oasmia Pharmaceutical AB (publ)'s score of 0.00 indicating that Evofem Biosciences is being referred to more favorably in the media.

Company Overall Sentiment
Evofem Biosciences Positive
Oasmia Pharmaceutical AB (publ) Neutral

0.2% of Evofem Biosciences shares are held by institutional investors. Comparatively, 0.1% of Oasmia Pharmaceutical AB (publ) shares are held by institutional investors. 0.0% of Evofem Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Evofem Biosciences has a beta of -1.32, meaning that its share price is 232% less volatile than the S&P 500. Comparatively, Oasmia Pharmaceutical AB (publ) has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500.

Evofem Biosciences has a net margin of -46.42% compared to Oasmia Pharmaceutical AB (publ)'s net margin of -8,633.64%. Oasmia Pharmaceutical AB (publ)'s return on equity of -43.94% beat Evofem Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Evofem Biosciences-46.42% -91.97% -61.93%
Oasmia Pharmaceutical AB (publ) -8,633.64%-43.94%-28.92%

Summary

Evofem Biosciences beats Oasmia Pharmaceutical AB (publ) on 7 of the 10 factors compared between the two stocks.

How does Oasmia Pharmaceutical AB (publ) compare to Graybug Vision?

Graybug Vision (NASDAQ:GRAY) and Oasmia Pharmaceutical AB (publ) (NASDAQ:OASM) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, media sentiment, earnings, analyst recommendations, profitability and risk.

Oasmia Pharmaceutical AB (publ) has lower revenue, but higher earnings than Graybug Vision.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Graybug Vision$426.96M0.00-$35.60M-$24.23N/A
Oasmia Pharmaceutical AB (publ)$220K0.00-$18.95MN/AN/A

In the previous week, Graybug Vision's average media sentiment score of 0.84 beat Oasmia Pharmaceutical AB (publ)'s score of 0.00 indicating that Graybug Vision is being referred to more favorably in the media.

Company Overall Sentiment
Graybug Vision Positive
Oasmia Pharmaceutical AB (publ) Neutral

Graybug Vision has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500. Comparatively, Oasmia Pharmaceutical AB (publ) has a beta of 0.96, indicating that its share price is 4% less volatile than the S&P 500.

49.9% of Graybug Vision shares are owned by institutional investors. Comparatively, 0.1% of Oasmia Pharmaceutical AB (publ) shares are owned by institutional investors. 7.9% of Graybug Vision shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Graybug Vision has a net margin of 0.00% compared to Oasmia Pharmaceutical AB (publ)'s net margin of -8,633.64%. Oasmia Pharmaceutical AB (publ)'s return on equity of -43.94% beat Graybug Vision's return on equity.

Company Net Margins Return on Equity Return on Assets
Graybug VisionN/A -77.61% -71.34%
Oasmia Pharmaceutical AB (publ) -8,633.64%-43.94%-28.92%

Summary

Graybug Vision beats Oasmia Pharmaceutical AB (publ) on 6 of the 9 factors compared between the two stocks.

How does Oasmia Pharmaceutical AB (publ) compare to Athersys?

Athersys (NASDAQ:ATHX) and Oasmia Pharmaceutical AB (publ) (NASDAQ:OASM) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, media sentiment, earnings, analyst recommendations, profitability and risk.

Athersys has a net margin of 0.00% compared to Oasmia Pharmaceutical AB (publ)'s net margin of -8,633.64%. Athersys' return on equity of 0.00% beat Oasmia Pharmaceutical AB (publ)'s return on equity.

Company Net Margins Return on Equity Return on Assets
AthersysN/A N/A -223.03%
Oasmia Pharmaceutical AB (publ) -8,633.64%-43.94%-28.92%

19.4% of Athersys shares are owned by institutional investors. Comparatively, 0.1% of Oasmia Pharmaceutical AB (publ) shares are owned by institutional investors. 0.0% of Athersys shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Oasmia Pharmaceutical AB (publ) has higher revenue and earnings than Athersys.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Athersys$146K0.00-$72.53M-$2.03N/A
Oasmia Pharmaceutical AB (publ)$220K0.00-$18.95MN/AN/A

In the previous week, Athersys' average media sentiment score of 0.00 equaled Oasmia Pharmaceutical AB (publ)'saverage media sentiment score.

Company Overall Sentiment
Athersys Neutral
Oasmia Pharmaceutical AB (publ) Neutral

Athersys has a beta of -0.9, indicating that its share price is 190% less volatile than the S&P 500. Comparatively, Oasmia Pharmaceutical AB (publ) has a beta of 0.96, indicating that its share price is 4% less volatile than the S&P 500.

Summary

Athersys and Oasmia Pharmaceutical AB (publ) tied by winning 4 of the 8 factors compared between the two stocks.

Get Oasmia Pharmaceutical AB (publ) News Delivered to You Automatically

Sign up to receive the latest news and ratings for OASM and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OASM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OASM vs. The Competition

Export
MetricOasmia Pharmaceutical AB (publ)Pharmaceutical Preparations IndustryMedical SectorNASDAQ Exchange
Market Cap$375K$886.55M$6.25B$11.77B
Dividend YieldN/A4.84%2.74%5.26%
P/E RatioN/A1.7129.2527.07
Price / SalesN/A120.63504.6873.47
Price / CashN/A20.0743.3053.90
Price / BookN/A7.609.676.69
Net Income-$18.95M-$4.80M$3.55B$332.64M

Oasmia Pharmaceutical AB (publ) Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OASM
Oasmia Pharmaceutical AB (publ)
N/AN/AN/AN/A$375K$220KN/A57
VAXX
Vaxxinity
N/A$0.01
+9,900.0%		N/AN/A$1.27MN/AN/A90
ASLN
ASLAN Pharmaceuticals
N/A$0.60
flat		N/AN/A$1.23M$12MN/A30
EVFM
Evofem Biosciences
N/A$0.01
flat		N/AN/A$1.15M$11.39MN/A120
GRAY
Graybug Vision
N/A$0.58
+0.8%		N/AN/A$918K$426.96MN/A27

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:OASM) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel